Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480725 | 0.81 | FDFT1 (0.34) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL22736214 | 0.81 | FDFT1 (0.34) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL30550903 | 0.78 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL2593552 | 0.78 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL18724653 | 0.78 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4CYP11B1CYP19A1 | |
| SCHEMBL4373548 | 0.78 | NPC1 (0.42) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL30955208 | 0.78 | NPC1 (0.42) | FDFT1CHRNB2CHRNA4 | |
| SCHEMBL28571826 | 0.76 | HTR2A (0.34) | FDFT1CHRNB2CHRNA4CYP11B1 | |
| SCHEMBL21834709 | 0.76 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4CYP19A1 | |
| SCHEMBL1842272 | 0.76 | FDFT1 (0.35) | FDFT1CHRNB2CHRNA4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253749-B1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2021-12-08 | — | — | EP | disclosed |
| EP-3253749-B1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2021-12-08 | — | — | EP | disclosed |
| CN-107531685-B | Compounds with antitumor activity | AB科学有限公司 | 2021-04-23 | — | — | CN | disclosed |
| EP-3053920-B1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2020-04-08 | — | — | EP | disclosed |
| US-10570122-B2 | Compounds with anti-tumoral activity | AB SCIENCE (FR) | 2020-02-25 | — | — | US | disclosed |
| US-10570122-B2 | Compounds with anti-tumoral activity | AB SCIENCE (FR) | 2020-02-25 | — | — | US | disclosed |
| US-20180202388-A1 | PISTON FOR AN INTERNAL COMBUSTION ENGINE AND METHOD FOR PRODUCING THE PISTON FOR AN INTERNAL COMBUSTION ENGINE | FELT PRODUCTS MFG. CO. LLC | 2018-07-19 | — | — | US | disclosed |
| US-20180202388-A1 | PISTON FOR AN INTERNAL COMBUSTION ENGINE AND METHOD FOR PRODUCING THE PISTON FOR AN INTERNAL COMBUSTION ENGINE | FELT PRODUCTS MFG. CO. LLC | 2018-07-19 | — | — | US | disclosed |
| US-20180202388-A1 | PISTON FOR AN INTERNAL COMBUSTION ENGINE AND METHOD FOR PRODUCING THE PISTON FOR AN INTERNAL COMBUSTION ENGINE | FELT PRODUCTS MFG. CO. LLC | 2018-07-19 | — | — | US | disclosed |
| US-20180079747-A1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2018-03-22 | — | — | US | disclosed |
| WO-2007139589-A1 | SUSTAINED RELEASE GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007109290-A2 | WATER-SOLUBLE ZINC IONOPHORES, ZINC CHELATORS, AND/OR ZINC COMPLEXES AND USE FOR TREATING CANCER | PHARMACYCLICS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219276-A1 | WATER-SOLUBLE ZINC IONOPHORES, ZINC CHELATORS, AND/OR ZINC COMPLEXES AND USE FOR TREATING CANCER | PHARMACYCLICS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | disclosed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | FDFT1 4319/4885CHRNB2 1339/4885CHRNA4 2682/4885 |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | GLP1R, GIPR, IAPP | FDFT1 3439/4885CHRNB2 2625/4885CHRNA4 3042/4885 |
| US-10570122-B2 | Compounds with anti-tumoral activity | MKI67, GZMB, RB1 | FDFT1 2678/4885CHRNB2 4751/4885CHRNA4 4858/4885 |
| US-20070099835-A1 | Sustained release GLP-1 receptor modulators | GLP1R, GIPR, GRPR | FDFT1 3473/4885CHRNB2 1715/4885CHRNA4 1819/4885 |
| US-20180079747-A1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | MKI67, TP53, VHL | FDFT1 2769/4885CHRNB2 4751/4885CHRNA4 4867/4885 |
| US-20070219276-A1 | WATER-SOLUBLE ZINC IONOPHORES, ZINC CHELATORS, AND/OR ZINC COMPLEXES AND USE FOR TREATING CANCER | SLC39A11, SLC39A3, SLC30A6 | FDFT1 4221/4885CHRNB2 4589/4885CHRNA4 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.